As of 2023-11-29, the Relative Valuation of Supernus Pharmaceuticals Inc (SUPN) is 13.36 USD. This relative valuation is based on P/E multiples. With the latest stock price at 26.97 USD, the upside of Supernus Pharmaceuticals Inc based on Relative Valuation is -50.5%.
The range of the Relative Valuation is 8.68 - 19.39 USD.
| Range | Selected | |
| Trailing P/E multiples | 18.5x - 23.3x | 19.4x |
| Forward P/E multiples | 19.9x - 24.1x | 21.9x |
| Fair Price | 8.68 - 19.39 | 13.36 |
| Upside | -67.8% - -28.1% | -50.5% |
| Date | P/E |
| 2023-11-28 | 57.51 |
| 2023-11-27 | 57.77 |
| 2023-11-24 | 59.35 |
| 2023-11-22 | 58.45 |
| 2023-11-21 | 58.07 |
| 2023-11-20 | 58.24 |
| 2023-11-17 | 58.49 |
| 2023-11-16 | 59.45 |
| 2023-11-15 | 60.97 |
| 2023-11-14 | 59.79 |
| 2023-11-13 | 58.28 |
| 2023-11-10 | 56.83 |
| 2023-11-09 | 55.74 |
| 2023-11-08 | 50.15 |
| 2023-11-07 | 50.88 |
| 2023-11-06 | 51.24 |
| 2023-11-03 | 52.20 |
| 2023-11-02 | 51.33 |
| 2023-11-01 | 50.99 |
| 2023-10-31 | 50.86 |
| 2023-10-30 | 50.37 |
| 2023-10-27 | 50.24 |
| 2023-10-26 | 48.45 |
| 2023-10-25 | 49.58 |
| 2023-10-24 | 51.18 |
| 2023-10-23 | 50.67 |
| 2023-10-20 | 51.84 |
| 2023-10-19 | 50.71 |
| 2023-10-18 | 53.80 |
| 2023-10-17 | 55.34 |
| 2023-10-16 | 55.06 |
| 2023-10-13 | 52.97 |
| 2023-10-12 | 55.10 |
| 2023-10-11 | 57.70 |
| 2023-10-10 | 58.28 |
| 2023-10-09 | 58.39 |
| 2023-10-06 | 58.51 |
| 2023-10-05 | 58.34 |
| 2023-10-04 | 57.38 |
| 2023-10-03 | 57.77 |
| 2023-10-02 | 57.83 |
| 2023-09-29 | 58.79 |
| 2023-09-28 | 59.88 |
| 2023-09-27 | 60.94 |
| 2023-09-26 | 62.29 |
| 2023-09-25 | 60.90 |
| 2023-09-22 | 60.07 |
| 2023-09-21 | 58.92 |
| 2023-09-20 | 58.98 |
| 2023-09-19 | 60.65 |